Intermittent fasting

Intervention1 paper6 findings

In one mouse study, alternate-day fasting protects against liver fibrosis, increases hepatocyte Nos3 and reduces Sdhaf4. Reviews link intermittent fasting to improved healthspan, AMPK activation and mTOR inhibition.

Animals1

Outcomes

Sdhaf4

downin mice1

1 study

Intermittent fasting decreases Sdhaf4 in mice.
“Mechanistically, ADF downregulates the mitochondrial chaperone SDHAF4, thereby suspending complex II assembly and promoting eNOS-derived nitric oxide (NO) production.”
Animalsalternate-day fastinghepatocyte
Alternate-day fasting resolves liver fibrosis via hepatocyte eNOS signaling · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 27 Sep 2026

Sdhaf4 →

Nos3

upin mice1

1 study

Intermittent fasting increases Nos3 in mice.
“ADF enhanced hepatocyte eNOS expression, and hepatocyte-specific eNOS knockout abolished the protective metabolic and anti-fibrotic effects of ADF.”
Animalsalternate-day fastinghepatocyte
Alternate-day fasting resolves liver fibrosis via hepatocyte eNOS signaling · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 27 Sep 2026

Nos3 →

Liver fibrosis

downin mice1

1 study

Intermittent fasting protects against liver fibrosis in mice.
“We further establish that the anti-fibrotic benefits of alternate-day fasting (ADF) critically depend on this intercellular pathway.”
Animalsalternate-day fastingliver
Alternate-day fasting resolves liver fibrosis via hepatocyte eNOS signaling · Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 27 Sep 2026

Liver fibrosis →

Healthspan

upin reviews1

1 study